Literature DB >> 18632301

Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number.

B Gómez-Ansón1, M Alegret, E Muñoz, G C Monté, E Alayrach, A Sánchez, M Boada, E Tolosa.   

Abstract

PURPOSE: To investigate grey matter volumes on magnetic resonance imaging (MRI) in preclinical Huntington's disease (HD), and their relationship to neuropsychology and CAG number.
MATERIAL AND METHODS: Twenty preclinical HD carriers and 21 healthy controls matched for age, sex, and educational level were included in this study. Clinical (UHDRS), and detailed neuropsychological assessments, and 3D IR SPGR axial MR acquisition. Calculation of global, segmented (SIENAX), and focal (voxel based morphometry, VBM) grey matter volumes was carried out. An analysis of variance (ANOVA) and a general linear model for VBM analysis were used to compare preclinical HD carriers and controls. Small volume correction was used, and clusters at p<0.05 were considered significant. Correlation analysis (VBM) with neuropsychology, and CAG number was also performed.
RESULTS: Preclinical HD carriers showed, compared to controls, smaller global volumes of the brain (1279+/-6 vs. 1331+/-46, p=0.003), total (666+/-48 vs. 698+/-34, p=0.020) and cortical grey matter (551+/-44 vs. 577+/-32, p=0.035). When compared to the controls, preclinical carriers showed focal volume losses, which were more prominent in the left prefrontal cortex, cerebellum, and right posterior temporal cortex. Preclinical HD performed slower in a visuomotor integration task, the 15-Objects test, than controls (t (1,25.02)=3.69; p=0.001: pre-HD: 69.55+/-28.86; controls: 45.79+/-8.38). A correlation was found between volume loss in the prefrontal cortex, visuomotor performance, and CAG number.
CONCLUSION: Preclinical HD carriers show grey matter volume reduction involving the prefrontal cortex, which relates to the visuomotor performance and CAG number. This suggests that regionally selective neuronal loss/dysfunction occurs prior to the clinical onset of symptoms.

Entities:  

Mesh:

Year:  2008        PMID: 18632301     DOI: 10.1016/j.parkreldis.2008.05.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  18 in total

1.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

2.  Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease.

Authors:  Robert Christian Wolf; Philipp Arthur Thomann; Fabio Sambataro; Nadine Donata Wolf; Nenad Vasic; G Bernhard Landwehrmeyer; Sigurd Dietrich Süßmuth; Michael Orth
Journal:  J Neurol       Date:  2015-01-28       Impact factor: 4.849

3.  Brain perfusion correlates of visuoperceptual deficits in mild cognitive impairment and mild Alzheimer's disease.

Authors:  Montserrat Alegret; Georgina Vinyes-Junqué; Mercè Boada; Pablo Martínez-Lage; Gemma Cuberas; Ana Espinosa; Isabel Roca; Isabel Hernández; Sergi Valero; Maitée Rosende-Roca; Ana Mauleón; James T Becker And; Lluís Tárraga
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Quantifying the Onset of Unintended Weight Loss in Huntington's Disease: A Retrospective Analysis of Enroll-HD.

Authors:  Amy C Ogilvie; Peg C Nopoulos; Jordan L Schultz
Journal:  J Huntingtons Dis       Date:  2021

5.  Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease.

Authors:  Montse Alegret; Mercè Boada-Rovira; Georgina Vinyes-Junqué; Sergi Valero; Ana Espinosa; Isabel Hernández; Gemma Modinos; Maitee Rosende-Roca; Ana Mauleón; James T Becker; Lluís Tárraga
Journal:  J Clin Exp Neuropsychol       Date:  2009-01-14       Impact factor: 2.475

6.  Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.

Authors:  Robert Christian Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine Donata Wolf; Philipp Arthur Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  Hum Brain Mapp       Date:  2011-08-25       Impact factor: 5.038

7.  Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis.

Authors:  Imis Dogan; Simon B Eickhoff; Jörg B Schulz; N Jon Shah; Angela R Laird; Peter T Fox; Kathrin Reetz
Journal:  Neurodegener Dis       Date:  2012-08-23       Impact factor: 2.977

8.  Scanning Patterns of Faces do not Explain Impaired Emotion Recognition in Huntington Disease: Evidence for a High Level Mechanism.

Authors:  Marieke van Asselen; Filipa Júlio; Cristina Januário; Elzbieta Bobrowicz Campos; Inês Almeida; Sara Cavaco; Miguel Castelo-Branco
Journal:  Front Psychol       Date:  2012-02-16

9.  Voxel-based morphometry with templates and validation in a mouse model of Huntington's disease.

Authors:  Stephen J Sawiak; Nigel I Wood; Guy B Williams; A Jennifer Morton; T Adrian Carpenter
Journal:  Magn Reson Imaging       Date:  2013-07-06       Impact factor: 2.546

10.  Huntington's disease mouse models online: high-resolution MRI images with stereotaxic templates for computational neuroanatomy.

Authors:  Stephen J Sawiak; Nigel I Wood; T Adrian Carpenter; A Jennifer Morton
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.